Danazol

Danazol, also known as Danocrine, is a medicine used to treat endometriosis, fibrocystic breast disease, hereditary angioedema, and other diseases. The masculinizing adverse effects of danazol, such as voice deepening, acne, and excessive hair growth, limit its use. After its discovery in 1963, danazol received FDA approval for medical usage in 1971. Gonadotropin-releasing hormone analogs, or GnRH analogs, have essentially supplanted danazol in the treatment of endometriosis due to their superior side-effect profiles, particularly their lack of masculinizing side effects. Danazol’s pharmacology is complex, with several modes of action. Direct inhibition of steroidogenesis-related enzymes, direct binding to and occupation of steroid hormone carrier proteins, followed by steroid hormone displacement from these proteins, and direct binding to and activation of sex hormone receptors are a few examples. The medication is categorized as a weak progestogen, weak antigonadotropin, weak... Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Rights and permissions Copyright information © 2024 Springer Nature Singapore Pte Ltd. About this entry Cite this entry (2024). Danazol. In: Dictionary of Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-99-9283-6_663 Download citation DOI: https://doi.org/10.1007/978-981-99-9283-6_663 Published: Publisher Name: Springer, Singapore Print ISBN: 978-981-99-9282-9 Online ISBN: 978-981-99-9283-6 eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences